CDK 4/6 Inhibitor Ribociclib Improves Overall Survival for Premenopausal Women With Metastatic, Hormone Receptor-Positive Breast Cancer

Updated MONALEESA-7 results, presented at ASCO, show ribociclib with hormonal therapy leads to longer overall survival than hormonal therapy alone
ASCO Coverage
June 5, 2019
By: 
Eric Fitzsimmons, Copy Editor and Content Coordinator

The addition of the CDK 4/6 inhibitor ribociclib (Kisqali) to hormonal therapy as the first treatment for premenopausalinfo-icon women with metastatic, hormone-receptor positive breast cancer, resulted in women living longer than they would if given hormonal therapyinfo-icon alone. These updated results from the phase III MONALEESA-7 trial were presented at the 2019 ASCO Annual Meeting on Tuesday.

The MONALEESA-7 trial previously proved that adding ribociclib to hormonal therapy helped women go longer without breast cancer growing, called progression-free survivalinfo-icon. Medicines for metastatic disease often get approval based on measures like progression-free survival. But overall survival, the length of time from the start of treatment until death, is the most important goal for trials of medicines because it helps show by how much the medicineinfo-icon might lengthen a person’s life. Overall survival is more difficult for clinical trials to show, and it often takes longer to find this effect.

The trial included 672 premenopausal women – women who still have regular periods – who were assigned to get either

  • ribociclib, hormonal therapy, and goserelininfo-icon (Zoladex), a medicine that suppresses the function of the ovaries, or
  • a placeboinfo-icon, hormonal therapy, and goserelin

The results presented this week show that adding ribociclib to hormonal therapy resulted in a 29 percent reduction in the risk of death compared to hormonal therapy given with a placebo. Researchers found that 42 months after starting treatment

  • 46.0 percent of women given placebo and hormonal therapy were still alive
  • 70.2 percent of women given ribociclib and hormonal therapy were still alive

Researchers reported that 35 percent of women assigned to the ribociclib plus hormonal therapy group were still receiving that treatment at the time of this analysis.

Ribociclib and other CDK 4/6 inhibitors are FDAinfo-icon approved and part of standard care for metastaticinfo-icon, hormoneinfo-icon-receptorinfo-icon positive breast cancer. The researchers for MONALEESA-7 note that this is the first time a CDK 4/6 inhibitor, given with hormonal therapy, has shown an overall survival benefit that is statistically significantinfo-icon, meaning it isn’t likely the result of chance. These findings strengthen the continued use of ribociclib and CDK 4/6 inhibitors in metastatic, hormone receptorinfo-icon-positive breast cancer.

You must have Javascript enabled to use this form.
Additional Related Topics 
Hormone Receptor-Positive
Metastatic
Targeted Therapy